Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma

November 11, 2022

By Alfred Garfall, MD
Edward A. Stadtmauer, MD

Video

Centering discussion on a patient case of transplant-eligible newly diagnosed multiple myeloma, expert panelists define high-risk disease and how it impacts treatment.

EP: 1.Patient Case 1: Transplant-Eligible Newly Diagnosed Multiple Myeloma

EP: 2.Recent Updates on Treatment Options for Patients With Transplant-Eligible NDMM

EP: 3.Selecting the Optimal Induction Therapy in Transplant-Eligible Newly Diagnosed Multiple Myeloma

EP: 4.Consolidation and Maintenance Therapy in Transplant-Eligible NDMM

Now Viewing

EP: 5.Patient Case 2: High-Risk Transplant-Eligible Newly Diagnosed Multiple Myeloma

EP: 6.Selecting Induction Therapy for Patients With High-Risk Transplant-Eligible NDMM

EP: 7.Transplant-Eligible NDMM: Optimizing Therapy for Efficacy and Tolerability

EP: 8.Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma

EP: 9.Selecting the Optimal Therapy for Patients With Transplant-Ineligible NDMM

EP: 10.Treatment Response and Duration of Therapy in Transplant-Ineligible NDMM

EP: 11.University of Pennsylvania Experts Discuss Treatment Options in Transplant-Eligible and -Ineligible Newly Diagnosed Multiple Myeloma

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!